U.S. SUCRALFATE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

U.S. Sucralfate Market Size and Trends: 2026-2033

The U.S. Sucralfate Market is estimated to be valued at USD 100 Mn in 2026 and is expected to reach USD 125 Mn by 2033, growing at a compound annual growth The rate (CAGR) of 3.2% from 2026 to 2033.

Key Takeaways

• Based on Formulation, the Tablet segment is expected to lead the market with 66.20 % share in 2026, due to its wide prescription preference in gastrointestinal treatment and ease of administration.
• Based on Indication, the Gastric Ulcers segment is expected to hold 34.60 % share of the market in 2026 reflecting prevalence and prescription trends.
• Based on Distribution Channel, the Retail Pharmacy segment is expected to hold 47.30 % share of the market in 2026 supported by chronic outpatient prescription patterns and strong pharmacy networks.
• Based on State, California is set to lead the market with 16.90 % share in 2026. While, New York is anticipated to be the fastest growing state.

Market Overview

The U.S. Sucralfate Market is advancing significantly, driven by its critical role in testing gastrointestinal disorders such as ulcers, GERD and bile reflux. The increasing demand for effective mucosal protective agents and the rising relevance of chronic and age-related conditions, often increased by aging populations and high NSAID usage, are expected to drive market growth over the forecast period.

Sucralfate formulations are high-affinity adherent solutions primarily categorized as tablets or oral suspensions that deliver a concentrated protective chemical bandage to the operative ulcer site. This allows for the stabilization of the mucosal barrier and supports faster tissue healing with a superior role in long-term safety and patient tolerability. These pharmaceutical interventions play a crucial role in modern healthcare sectors such as gastroenterology, intensive care (for stress ulcer prophylaxis), and pediatrics. This is owing to their ability to provide local, nonsystematic protection and minimize the risk of systematic side effects typically associated with long-term proton pump inhibitor (PPI) use.

The ongoing innovation in liquid suspension stability and enhanced bioadhesive technology is reshaping the sucralfate industry. The demand for flexible, high-performance delivery systems is increasing in hospitals, outpatient clinics, and specialized long-term care facilities. These advancements have expanded the functional scope of gastroprotective therapy by improving dosing accuracy, ensuring compatibility with enteral feeding tubes, and enabling precise mucosal coating across varying pH levels. The top players operating in the industry are focused on forming strategic acquisitions and launching refined generic versions designed mainly for streamlined digital pharmacy workflows and personalized patient treatment plans.

Current Events and Its Impacts on the U.S. Sucralfate Market

Segmental Insights

U.S. Sucralfate Market Insights, By Formulation – Tablet Leads Due to its Wide Prescription Preference

In terms of Formulation, the Tablet segment contributes the highest share of 66.20% in 2026 of the U.S. Sucralfate Market. This is owing to patient convenience and established clinical pathways. They are generally more cost-effective for both manufacturers and patients. Tablet formulation is the cornerstone for long-term maintenance therapy and chronic ulcer management. The formulation is the preferred choice for outpatient care due to their ease of storage and portability compared to liquid suspensions. The formulation is extensively used to treat duodenal ulcers and prevent their recurrence.

U.S. Sucralfate Market Insights, By Indication – Gastric Ulcers Leads with Prevalence and Prescription Trends

In terms of indication, the gastric ulcers segment contributes the highest share of 34.60% in the U.S. Sucralfate Market in 2026. This is because healthcare providers increasingly rely on localized mucosal protection for vulnerable patients. High rates of chronic nonsteroidal anti-inflammatory drugs (NSAID) use and persistent H. pylori infections generate a continuous demand for sucralfate’s unique chelating properties. The medication binds directly to the proteins in ulcerated tissue, which creates a durable physical barrier against corrosive stomach acid and pepsin. This bandage mechanism facilitates rapid tissue repair without interfering with the body’s natural pH balance. Rising concerns among medical professionals about the long-term effects of systematic acid suppressors have enabled this segment to capture a significant market share by providing a safe, site-specific alternative for the aging US population.

U.S. Sucralfate Market Insights, By Distribution Channel – Retail Pharmacy Leads with Chronic Outpatient Prescription Patterns

In terms of distribution channel, the retail pharmacy contributes the highest share of 47.30% in the U.S. Sucralfate Market in 2026 by serving as the primary access point for outpatient gastrointestinal care. These establishments manage the vast majority of sucralfate prescriptions and ensure that patients receive timely access to both cost-effective generic tablets and liquid suspensions. The retail pharmacists strengthen this segment by providing essential counseling on the specific administration protocols required for sucralfate to function correctly. Because the drug requires precise doing on an empty stomach, the face-to-face guidance found in retail settings remains a critical driver of patient compliance. The extensive geographic presence of these pharmacies ensures that sucralfate remains readily accessible to a broad range of patient populations in the US.

State Insights

California Sucralfate Market Analysis & Trends

California is set to lead the U.S. Sucralfate Market with a share of 16.90% owing to its massive population and sophisticated healthcare infrastructure. The increasing prevalence of gastrointestinal disorders is creating a steady and growing demand for mucosal protectants. A diverse demographic profile and the increasing number of prescriptions for NSAID-induced gastric injuries and H. pylori infections are influencing the market dynamics. The state's advanced medical networks like major hospital systems are propelling the utilization of sucralfate in both acute inpatient care and long-term maintenance therapy for duodenal ulcers. In addition, the presence of major generic pharmaceutical players like Teva Pharmaceuticals and Mylan contributes to a strong supply chain across the state. There is a growing demand for specialized formulations, such as chewable tablets, to improve patient compliance. The incorporation of digital health solutions, along with the expansion of online pharmacies, is likely to increase the use of sucralfate among both urban and rural populations in California.

New York Sucralfate Market Analysis & Trends

New York is likely to experience the fastest growth over the forecast period owing to the densest urban populations and a highly advanced healthcare infrastructure. The state is experiencing increasing incidence of gastrointestinal conditions. There is also a rising prevalence of H. pylori infections and chronic acid reflux heightened by the fast-paced lifestyle of metropolitan areas. This environment is propelling a high demand for sucralfate formulations. The medical institutions, including Mount Sinai and NYU Langone, use it for patients who do not respond to standard Proton Pump Inhibitors.

The top manufacturers like Teva Pharmaceuticals and Viatris are driving New York's strong supply chain, thus bolstering the market's strength. These firms provide cost-effective generic versions of Carafate, making them accessible to a diverse patient demographic, including the large geriatric population in the state. New York is strategically positioned to continue as a leading regional market due to its combination of high clinical demand and efficient pharmaceutical distribution channels.

Market Report Scope

U.S. Sucralfate Market Drivers

High prevalence of gastrointestinal (GI) disorders

The increasing prevalence of gastrointestinal disorders is the primary driver of the growth in the sucralfate market in the U.S. A growing number of people suffer from conditions like peptic ulcers, GERD, and gastritis, leading to a consistent clinical need for effective mucosal protective agents. One of the contributors to this demand is the prevalence of Helicobacter pylori infections, which affect over 35% of the U.S. population and are a leading cause of both duodenal and gastric ulcers. In addition, the increasing use of nonsteroidal anti-inflammatory drugs (NSAIDs) for chronic pain management in an aging population has resulted in a rise in NSAID-induced gastric mucosal injuries. Sucralfate works locally by binding to the ulcer site to create a protective barrier against acid and pepsin. Sucralfate continues to be a favored therapeutic option for patients who do not respond to systemic acid suppressants or need targeted gastric protection.

Increasing collaboration and acquisition strategies adopted by market players

The U.S. sucralfate market is expected to witness significant growth, owing to increasing inorganic growth strategies such as collaboration and acquisitions by market players. Increasing applications and uses of sucralfate in the U.S. is expected to drive the market growth. Moreover, increasing prevalence of gastro-esophageal reflux disease (GERD) and Helicobacter pylori infection is expected to bolster the U.S. sucralfate market over the forecast period.

Analyst Opinion (Expert Opinion)

• The U.S. sucralfate market reflects a mature and clinically stable segment within gastrointestinal therapeutics, supported by consistent prescription demand and long-standing clinical use. Prescription data indicates that sucralfate remains widely utilized in the U.S., with approximately 1.49 million prescriptions issued annually and more than 500,000 patients receiving therapy, underscoring its continued relevance in ulcer management and mucosal protection.
• Sucralfate is primarily prescribed for the treatment and prevention of duodenal and gastric ulcers. Epidemiological data suggests that millions of individuals in the U.S. experience peptic ulcer disease each year, creating a sustained patient pool for ulcer-healing and protective agents. Despite competition from acid-suppressive therapies, sucralfate maintains clinical adoption due to its non-systemic mechanism of action and favorable safety profile in specific patient populations.
• Tablets account for a significant portion of prescriptions, driven by standardized dosing and physician familiarity, while oral suspensions continue to see use in hospital settings and among patients with swallowing difficulties. Retail pharmacies represent a major distribution channel, supported by strong generic availability and established supply chains.
• North America contributes a substantial share of global sucralfate consumption, reflecting high diagnostic rates of gastrointestinal disorders and access to healthcare services in the U.S. Overall, the market demonstrates steady demand fundamentals, shaped by chronic gastrointestinal conditions, an aging population, and continued reliance on cost-effective generic formulations.

U.S. Sucralfate Industry News

• In May 2024, Strides Pharma Science Limited made an announcement that its completely-owned subsidiary, Strides Pharma Global Pte. Limited, based in Singapore, has secured approval from the United States Food and Drug Administration (USFDA) for the generic version of Sucralfate Oral Suspension, 1 gm/10 mL.
• In May 2024, the FDA approved Abon Pharmaceuticals' ANDA for a generic version of Carafate® (sucralfate) Oral Suspension at a concentration of 1 g/10 ml. The projected annual sales of sucralfate oral suspension in the U.S. market are estimated to be USD 146 million.

Market Segmentation

• Formulation Insights (Revenue, USD Mn, 2026 - 2033)
• Tablet
• Liquid Suspension
• Indication Insights (Revenue, USD Mn, 2026 - 2033)
• Gastric Ulcers
• Duodenal Ulcers
• Gastro Esophageal Reflux Disease (GERD)
• Others
• Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• State Insights (Revenue, USD Mn, 2026 - 2033)
• Illinois
• Texas
• New York
• California
• Others
• Key Players Insights
• Teva Pharmaceutical Industries Ltd.
• Allergan plc
• Vertice Pharma LLC
• Pharmaceutical Associates Inc. (PAI)

Sources

Primary Research Interviews

• Pharmaceutical API Manufacturers (Sucralfate)
• Branded & Generic Drug Manufacturers
• Gastroenterology Drug Formulation Experts
• Contract Manufacturing Organizations (CMOs)
• Hospital & Retail Pharmacists
• Regulatory & Quality Compliance Consultants
• Others

Databases

• Bloomberg Terminal
• Thomson Reuters Eikon
• IQVIA MIDAS
• FDA Orange Book & Drug Establishments Database
• Others

Magazines

• Pharmaceutical Technology Magazine
• Drug Development & Delivery
• Pharmaceutical Executive
• American Journal of Managed Care (AJMC)
• Chemical & Engineering News
• Others

Journals

• Journal of Gastroenterology
• Alimentary Pharmacology & Therapeutics
• American Journal of Gastroenterology
• Journal of Pharmaceutical Sciences
• Drug Development and Industrial Pharmacy
• Others

Newspapers

• The Wall Street Journal
• Financial Times
• Reuters
• Bloomberg News
• STAT News
• Others

Associations

• American Gastroenterological Association (AGA)
• Pharmaceutical Research and Manufacturers of America (PhRMA)
• Generic Pharmaceutical Association (GPhA)
• International Society for Pharmaceutical Engineering (ISPE)
• U.S. Pharmacopeia (USP)
• Others

Public Domain Sources

• U.S. Food and Drug Administration (FDA)
• Centers for Medicare & Medicaid Services (CMS)
• National Institutes of Health (NIH)
• National Library of Medicine (PubMed)
• U.S. Census Bureau
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 8 Years